Gland PharmaNSE:GLAND +0.40%84 ROC (Joel Greenblatt) % is 29.03% as of Mar. 2026, which is 3% below its 10-year median of 29.81. GuruFocus rates NSE:GLAND with a GF Score™ of 84/100 and a GF Value™ of ₹2,136.46 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 978 Drug Manufacturers companies, Gland Pharma ranks better than 67.48% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Gland Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 29.03%.
The historical rank and industry rank for Gland Pharma's ROC (Joel Greenblatt) % or its related term are showing as below:
NSE:GLAND'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 17.73 Med: 29.81 Max: 46.72
Current: 22.62
During the past 9 years, Gland Pharma's highest ROC (Joel Greenblatt) % was 46.72%. The lowest was 17.73%. And the median was 29.81%.
NSE:GLAND's ROC (Joel Greenblatt) % is ranked better than 67.48% of 978
companies
in the Drug Manufacturers industry
Industry Median: 11.495
vs NSE:GLAND: 22.62
Gland Pharma's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -17.60% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Gland Pharma ROC (Joel Greenblatt) % Related Terms
Gland Pharma ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Gland Pharma's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:GLAND vs ZTS, UTHR: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Gland Pharma's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gland Pharma ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gland Pharma's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Gland Pharma's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 29.03% mean?
Gland Pharma (NSE:GLAND) has a ROC (Joel Greenblatt) % of 29.03% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Gland Pharma and its competitors. This is near median its historical median of 29.81. Over the past decade, Gland Pharma's ROC (Joel Greenblatt) % has ranged from 17.73 to 46.72. According to the industry distribution chart, Gland Pharma ranks #318 out of 978 companies in the Drug Manufacturers industry, placing it in the top 32.5%.
Is Gland Pharma's ROC (Joel Greenblatt) % too high?
Gland Pharma's current ROC (Joel Greenblatt) % of 29.03% is near median its 10-year median of 29.81. Over the past 10 years, this metric has ranged from a low of 17.73 to a high of 46.72. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.50. Gland Pharma's value of 29.03% is 152.5% above this industry median. Based on the distribution chart, Gland Pharma ranks #318 out of 978 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Gland Pharma has a GF Score™ of 84/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's ROC (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Gland Pharma ranks #318 out of 978 companies for ROC (Joel Greenblatt) %. This puts Gland Pharma in the upper half of its industry. The industry median ROC (Joel Greenblatt) % is 11.50. Gland Pharma's value of 29.03% is 152.5% above this benchmark. Historically, Gland Pharma's own ROC (Joel Greenblatt) % has ranged from 17.73 to 46.72 over the past decade. While the company's 10-year median is 29.81 vs. the industry median of 11.50, Gland Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.50, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gland Pharma's current ROC (Joel Greenblatt) % of 29.03% is 152.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Gland Pharma and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gland Pharma's current ROC (Joel Greenblatt) % is 29.03%, which is near median its own 10-year median of 29.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,136.46, compared to a current price of ₹2,479.40 — trading 16.1% above its estimated fair value. The current ROC (Joel Greenblatt) % is 29.03%, which is near median its 10-year median of 29.81 and 152.5% above the Drug Manufacturers industry median of 11.50. Gland Pharma's overall GF Score™ is 84/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current ROC (Joel Greenblatt) % is 29.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gland Pharma (NSE:GLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued.
The current stock price of ₹2,479.40 is trading 16.1% above its estimated GF Value™ of ₹2,136.46.
GuruFocus considers Gland Pharma to be Modestly Overvalued.
Key valuation signals for NSE:GLAND:
ROC (Joel Greenblatt) %: 29.03% (near median its 10-year median of 29.81)
GF Value™: ₹2,136.46 vs. price of ₹2,479.40 (16.1% above fair value)
Industry Position: 152.5% above the Drug Manufacturers median (#318 of 978)
No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
84GF Score
Get the complete analysis for NSE:GLAND
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GLAND has been successfully added to your 
